These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6102774)

  • 21. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [FDA phase II and phase III drug evaluation of antipsychotic agents].
    Yagi K
    Seishin Shinkeigaku Zasshi; 1990; 92(9):584-92. PubMed ID: 1980369
    [No Abstract]   [Full Text] [Related]  

  • 23. On the usefulness of the placebo and of the double-blind technique in the evaluation of psychotropic drugs.
    Tétreault L; Bordeleau JM
    Psychopharmacol Bull; 1971 Jul; 7(3):44-64. PubMed ID: 4940648
    [No Abstract]   [Full Text] [Related]  

  • 24. Quetiapine: efficacy, tolerability and safety in schizophrenia.
    Miodownik C; Lerner V
    Expert Rev Neurother; 2006 Jul; 6(7):983-92. PubMed ID: 16831113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine for treatment of schizophrenia.
    Orr RD
    JAMA; 1996 Jan; 275(3):186-7. PubMed ID: 8604168
    [No Abstract]   [Full Text] [Related]  

  • 26. [Neuroleptic potency of bromperidol].
    Kaumeier S; Haase HJ; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Int Pharmacopsychiatry; 1978; 13 Suppl 1():41-4. PubMed ID: 35478
    [No Abstract]   [Full Text] [Related]  

  • 27. [Discourse on the double blind method. Institution and experimentation. 19366 RP].
    Constant J; Dubois J
    Rev Neuropsychiatr Infant; 1975; 23(5-6):329-43. PubMed ID: 240196
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological treatments of schizophrenia.
    Simpson GM
    Psychopharmacol Bull; 1986; 22(1):33-5, 42-3. PubMed ID: 2873617
    [No Abstract]   [Full Text] [Related]  

  • 29. Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia.
    Emsley R; Fleischhacker WW; Galderisi S; Halpern LJ; McEvoy JP; Schooler NR
    BMJ; 2016 Sep; 354():i4728. PubMed ID: 27613560
    [No Abstract]   [Full Text] [Related]  

  • 30. [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].
    Llorca PM; Wolf MA
    J Psychiatry Neurosci; 1991 Mar; 16(1):19-24. PubMed ID: 1675588
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical evaluation of ceruletide in schizophrenia: a multi-institutional cooperative double-blind controlled study.
    Itoh H; Shimazono Y; Kawakita Y; Kudo Y; Satoh Y; Takahashi R
    Psychopharmacol Bull; 1986; 22(1):123-8. PubMed ID: 3523572
    [No Abstract]   [Full Text] [Related]  

  • 32. Haase hermeneutics, or, the exegesis of the neuroleptic threshold.
    McEvoy JP; Kamaraju L; Nelson L
    J Clin Psychopharmacol; 1992 Feb; 12(1):64-5. PubMed ID: 1348062
    [No Abstract]   [Full Text] [Related]  

  • 33. [Long-term medication in schizophrenia (author's transl)].
    Pietzcker A
    Nervenarzt; 1978 Sep; 49(9):518-33. PubMed ID: 30051
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapeutic windows by placebo in schizophrenic patients under prolonged neuroleptic treatment].
    Etienne T; Lacroix R; Lacroix J
    Presse Med; 1991 Oct; 20(32):1570. PubMed ID: 1682917
    [No Abstract]   [Full Text] [Related]  

  • 35. Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophrenia.
    Lee J; Remington G
    Am J Psychiatry; 2014 Jan; 171(1):118-9. PubMed ID: 24399431
    [No Abstract]   [Full Text] [Related]  

  • 36. Method for evaluation of neuroleptic dosage reduction.
    Lonowski DJ; Sterling FE; Kennedy JC
    Psychol Rep; 1979 Feb; 44(1):15-20. PubMed ID: 37540
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of the drug 1-methyl-D-lysergic acid butanolamide or methysergide maleate in the treatment of chronic schizophrenia.
    Maire FW; Collins LG; Marks JB
    Int J Neuropsychiatry; 1967; 3(5):397-9. PubMed ID: 4866597
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: The use of placebos in clinical trials for acute schizophrenia.
    Zipursky RB
    Can J Psychiatry; 1995 Sep; 40(7):425-6. PubMed ID: 8548724
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug treatment of schizophrenia: current concepts.
    Naber D; Hippius H
    Pharmacopsychiatry; 1991 Mar; 24(2):43-4. PubMed ID: 1677202
    [No Abstract]   [Full Text] [Related]  

  • 40. Antipsychotic effect of gamma-type endorphins in schizophrenia.
    van Ree JM; de Wied D; Verhoeven WM; van Praag HM
    Lancet; 1980 Dec 20-27; 2(8208-8209):1363-4. PubMed ID: 6109172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.